SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently driving intense conversation after its recent earnings report significantly beat expectations and delivered robust guidance, sparking strong bullish sentiment around its AI growth while also reigniting debates over its high valuation.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney's stock is trending lower despite reporting strong earnings and an announced $7 billion share buyback, as the community actively debates the post-earnings sell-off and anticipates clarity on CEO succession amidst its multi-year underperformance.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradyne is trending following an exceptional earnings report and stronger-than-anticipated future guidance, which significantly exceeded expectations. The conversation highlights its accelerating momentum in AI-driven compute and chip testing demand, with many celebrating its impressive performance and future prospects.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is experiencing intense debate and price pressure amid its lock-up expiration, which has sparked widespread concerns over insider selling and its valuation. The community is sharply divided, with many seeing the stock as an oversold opportunity for a market-leading design platform, while others criticize it as an overhyped IPO facing headwinds from AI advancements.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus is trending following its latest earnings report, where robust overall performance was overshadowed by soft near-term revenue guidance, leading to a significant stock decline. The community is actively debating whether this represents an overreaction and a buying opportunity given the company's strong cash position and strategic role in the AI memory market, or if it signals valid execution risks.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is drawing significant attention following the Foundation's announcement of new board members and its relocation to the US, which has ignited intense community debate over management, potential token supply adjustments, and the project's long-term viability, while some investors view current prices as a prime accumulation opportunity amid wider crypto optimism.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience.   The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency &lt;1 second. The chain currently supports 100k orders / second.  The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1.   The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

HYPE CRYPTO is surging amid significant institutional interest and robust token buybacks, with its Hyperliquid platform breaking volume records and expanding accessibility. The community is hotly debating its potential to become a top-tier crypto, driven by its perceived "insane relative strength" and ongoing developments.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is sharply declining due to a broader crypto market sell-off and concerns about prediction market revenue, despite recent analyst upgrades and Cathie Wood increasing her stake. The community is actively debating if the stock is oversold and poised for a bounce ahead of upcoming earnings, or if crypto volatility will continue to weigh on its price.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is heavily trending as its Q2 earnings approach, with investors keenly focused on whether its anticipated massive revenue growth will confirm its critical role in AI infrastructure or if past management concerns and margin pressures will lead to disappointment. The community is also actively discussing its pivotal partnership with Elon Musk's xAI and the potential for a significant short squeeze.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF ($KWEB) is trending as China's market shows renewed strength, driven by anticipated policy support for tech and signs of easing US-China trade tensions, prompting significant bullish options activity and community discussion around undervaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Above 50 Day Moving Average - What's Next?

Minerva Neurosciences (NASDAQ:NERV) Stock Price Crosses Above 50 Day Moving Average - Here's What Happened...

Minerva Neurosciences (NASDAQ:NERV) Cut to Sell at Wall Street Zen

Wall Street Zen cut Minerva Neurosciences from a "hold" rating to a "sell" rating in a report on Sunday...

Minerva Neurosciences (NASDAQ:NERV) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised Minerva Neurosciences from a "sell" rating to a "hold" rating in a research note on Saturday...

<ul class="summary-bullets"><li>Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.</li><li>The FDA cleared the design for a confirmatory Phase 3 trial of roluperidone, a potential treatment for the negative symptoms of schizophrenia.</li><li>Retail traders on Stocktwits turned “extremely bullish,” citing the new funding and FDA alignment as signs of confidence in an eventual approval.</li></ul>Minerva Neurosciences' stock jumped to a nearly two-year high on Tuesday after the biotech firm announced a new financing deal that could bring in up to $200 million and outlined a clear regulatory path with the U.S. FDA for its lead schizophrenia drug, roluperidone.The company’s shares&nbsp;soared 141% to $6.41 on Tuesday, hitting their highest level since February 2024, before slipping 6.4% in after-hours trading.<h2 class="st-heading-2">Funding For Phase 3 Trial And NDA Resubmission</h2>Minerva said it raised $80 million upfront through a private financing round backed by leading healthcare investors, including Vivo Capital, Janus Henderson Investors, and Federated Hermes Kaufmann Funds.&nbsp;The deal could bring in as much as $200 million in total, with another $80 million tied to the exercise of Tranche A warrants and an additional $40 million linked to future clinical milestones under Tranche B warrants. Each preferred share was priced at $1,000, convertible into common stock at $2.11 pending shareholder approval.The firm said the investment would fully fund its planned confirmatory Phase 3 study of roluperidone, and NDA resubmission to the FDA. It will also be used to make preparations for a potential U.S. commercial launch, should the product gain approval.<h2 class="st-heading-2">Strengthening The Team</h2>Under the agreement, Minerva will increase the number of its directors to include up to three new members with significant experience in schizophrenia and drug development. The company also plans to establish a Scientific Advisory Board to help guide the Phase 3 study.“We will now refocus all of our efforts on the successful execution of the confirmatory trial with the objective of demonstrating that roluperidone can effectively treat patients with impairing negative symptoms,” CEO Remy Luthringer said in a statement.<h2 class="st-heading-2">FDA Agrees On Clear Trial Design</h2>The FDA has agreed on the design of the confirmatory Phase 3 study, which will test roluperidone 64 mg as a standalone treatment in patients with schizophrenia who suffer from negative symptoms such as lack of motivation, social withdrawal, and diminished emotional expression. The main goal of the trial will be to measure improvements in the PANSS Marder Negative Symptoms Factor Score after 12 weeks.The FDA has also asked Minerva to observe patients for up to 52 weeks to monitor relapse rates, helping to build evidence for roluperidone as a monotherapy. The company expects around 25%–30% of trial participants to be enrolled from U.S. sites.<h2 class="st-heading-2">Stocktwits Traders Eye FDA Milestone Upside</h2>On Stocktwits, retail sentiment for Minerva was ‘extremely bullish’ amid a 102,300% surge in 24-hour message volume.One user said they expected Minerva’s stock to climb sharply if it breaks past the $7 level, while another pointed to the company’s $200 million financing as a sign of confidence, suggesting that such investment likely reflects optimism around eventual FDA approval.<stembedurl>https://stocktwits.com/24cmKarMadhfromPrishtina/message/633140308</stembedurl><stembedurl>https://stocktwits.com/Myway1000/message/633126607</stembedurl><a href="https://stocktwits.com/symbol/NERV">Minerva’s stock</a> has nearly tripled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Minerva Neurosciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst

Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.

Equity

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.30	--	--	N/A
Q3 '25	--	-$0.36	--	N/A
Q2 '25	-$0.90	-$0.43	52.22%	BEAT
Q1 '25	-$1.07	-$0.50	53.27%	BEAT
Q4 '24	-$1.05	-$0.56	46.67%	BEAT

NERV
Minerva Neurosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest NERV News

NERVMinerva Neurosciences Inc